Nuclear Medicine and Biology
Volume 34, Issue 7 , Pages 757-778 , October 2007

Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view

Portions of this article were highlighted during a presentation at the Workshop on Molecular Imaging: After Bench to Bedside: Impact on Clinical Outcome, February 23–25, 2007.

Received 21 February 2007 ,Revised 29 March 2007 ,Accepted 4 April 2007.

References 

  1. Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Disc. 2004;3:488–496
  2. Govindan SV, Griffiths GL, Hansen HJ, Horak ID, Goldenberg DM. Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies. Tech Cancer Res Treat. 2005;4(4):375–391
  3. Ng DCE. Radioimmunotherapy: a brief overview. Biomed Imaging Interv J. 2006;2(3):e23
  4. Pohlman B, Sweetenham J, Macklis RM. Review of clinical radioimmunotherapy. Expert Rev Anticancer Ther. 2006;6(3):445–461
  5. Ehrlich P. The collected papers of Paul Ehrlich. vol 3. London: Pergamon; 1960;
  6. Pressman D. Tissue localizing antibodies. Ann N Y Acad Sci. 1955;59(3):376–380
  7. Mach JP, Carrel S, Merenda C, Sordat B, Cerottini JC. In vivo localization of radiolabeled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice. Nature. 1974;248(450):704–706
  8. Goldenberg DM, Preston DF, Primus FJ, Hansen HJ. Photoscan localization of GW-39 tumors in hamsters using radiolabeled anticarcinoembryonic antigen immunoglobulin G. Cancer Res. 1974;34(1):1–9
  9. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497
  10. Bierman PJ, Vose JM, Leichner PK, Quadri SM, Armitage JO, Klein JL, et al. Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease. J Clin Oncol. 1993;11(4):698–703
  11. Sharkey RM, Burton J, Goldenberg DM. Radioimmunotherapy of non-Hodgkin's lymphoma: a critical appraisal. Expert Rev Clin Immunol. 2005;1(1):47–62
  12. Jaffer FA, Weissleder R. Molecular imaging in the clinical arena. JAMA. 2005;293:855–862
  13. Kelloff GJ, Krohn KA, Larson SM, Weissleder R, Mankoff DA, Hoffman JM, et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res. 2005;11(22):7967–7985
  14. Barbet J, Chatal JF, Gauche F, Martino J. Which radionuclides will nuclear oncology need tomorrow?. Eur J Nucl Med Mol Imaging. 2006;33(6):627–630
  15. Carlsson J, Aronsson EF, Hietala SO, Stigbrand T, Tennvall J. Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol. 2003;66:107–117
  16. Anderson CJ, Connett JM, Schwarz SW, Rocque PA, Guo LW, Philpott GW, et al. Copper-64-labeled antibodies for PET imaging. J Nucl Med. 1992;33:1685–1691
  17. Anderson CJ, Schwarz SW, Connett JM, Cutler D, Guo LW, Germain CJ, et al. Preparation, biodistribution and dosimetry of 64Cu-labeled anti-colorectal carcinoma monoclonal antibody (MAb) fragments 1A3 F(ab′)2. J Nucl Med. 1995;36(5):850–858
  18. Anderson CJ, Schwarz SW, Connett JM, Rocque PA, Guo LW, Zinn KR, et al. Optimization of the preparation of 64Cu-labeled monoclonal antibody (MAb) fragments [1A3-F(ab′)2] for improved biodistribution. J Nucl Med. 1993;34:28P
  19. Verel I, Visser GWM, Boellaard R, Boerman OC, van Eerden J, Snow GB, et al. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med. 2004;44(10):1663–1670
  20. Verel I, Visser GWM, Boellaard R, Stigter M, Snow GB, van Dongen GAMS. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med. 2004;44(8):1271–1281
  21. Verel I, Visser GWM, Boerman OC, van Eerden J, Finn R, Boellaard R, et al. Long-lived positron emitters 89Zr and 124I for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm. 2004;18(4):655–660
  22. Verel I, Visser GWM, van Dongen GA. The promise of immunoPET in radioimmunotherapy. J Nucl Med. 2005;46:164S–171S
  23. Borjesson PKE, Jauw YWS, Boellaard R. Performance of immunoPET with 89Zr-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res. 2006;12:2133–2140
  24. Kocher DC. Radioactive decay tables. Oakridge: Office of Scientific and Technical Information, US Department of Energy; 1981;Accessed May 2007 at: http://www.osti.gov/energycitations/servlets/ purl/6085378-q8TFyb/native/6085378.pdf
  25. Katz L, Penfold AS. Range–energy relations for electrons and the determination of beta-ray end-point energies by absorption. Rev Mod Phys. 1952;24:28–44
  26. Leichner PK, Kwok CS. Tumor dosimetry in radioimmunotherapy: methods of calculation for beta particles. Med Phys. 1993;20(2 Pt 2):529–534
  27. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 1995;36(10):1902–1909
  28. Anderson CJ, Connett JM, Baumann ML, Schwarz SW, Zinn KR, Philpott GW, et al. Comparison of 67Cu and 64Cu as potential radionuclides for radiotherapy. J Nucl Med. 1993;34:134P
  29. Apelgot S, Coppey J, Gaudemer A, Grisvard J, Guille E, Sasaki I, et al. Similar lethal effect in mammalian cells for two radioisotopes of copper with different decay schemes, 64Cu and 67Cu. Int J Radiat Biol. 1989;55:365–384
  30. Behr TM, Behe M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, et al. High-linear energy transfer (LET) α versus low-LET β emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab′ fragments in a human colonic cancer model. Cancer Res. 1999;59:2635–2643
  31. Allen BJ, Raja C, Rizvi S, Li Y, Tsuji J, Zhang D, et al. Targeted alpha therapy for cancer. Phys Med Biol. 2004;49:3703–3712
  32. Fang N. Research on 212Pb- and 212Bi-radiopharmaceuticals for therapy. J Isot. 1997;10(2):114–118
  33. Henriksen G, Schoultz BW, Hoff P, Larsen RH. Potential in vivo generator for alpha-particle therapy with 212Bi: presentation of a system to minimize escape of daughter nuclide after decay of 212Pb to 212Bi. Breast Cancer Res Treat. 2003;2003(91):109–113
  34. Rotmensch J, Atcher RW, Schlenker R, Hines J, Grdina D, Block BS, et al. The effect of the α-emitting radionuclide 212Pb on human ovarian carcinoma: a potential new form of therapy. Gynecol Oncol. 1989;32:236–239
  35. Ruble G, Wu C, Squire RA, Gansow OA, Strand M. The use of 212Pb-labeled monoclonal antibody in the treatment of murine erthyroleukemia. Int J Radiat Oncol Biol Phys. 1996;34:609–616
  36. Su FM, Beaumier P, Axworthy D, Atcher R, Fritzberg A. Pre-targeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator. Nucl Med Biol. 2005;32:741–747
  37. Apostolidis C, Carlos-Marques R, Janssens W, Molinet R, Nikula T, Ouadi A. Production of carrier free 225Ac/213Bi from 229Th for alpha-immunotherapy. J Labelled Compd Radiopharm. 2001;44(1):5806–5808
  38. Apostolidis C, Carlos-Marques R, Janssens W, Nikula T, Ouadi A. Cancer treatment using 213Bi and 225Ac in radioimmunotherapy. Nucl News. 2001;29–33
  39. Apostolidis C, Molinet R, Rasmussen G, Morgenstern A. Production of 225Ac from 229Th for targeted α therapy. Anal Chem. 2005;77(19):6288–6291
  40. Ballangrud AM, Yang WH, Charlton DE, McDevitt MR, Hamacher KA, Panageas KS, et al. Response of LNCaP spheroids after treatment with an α-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res. 2001;61:2008–2014
  41. Ballangrud AM, Yang WH, Palm S, Enmon R, Borchardt PE, Pellegrini VA, et al. Alpha-particle emitting atomic generator 225Ac-labeled trastuzumab (Herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin Cancer Res. 2004;10:4489–4497
  42. Boll RA, Malkemus D, Mirzadeh S. Production of 225Ac for alpha particle mediated radioimmunotherapy. Appl Radiat Isot. 2005;62:667–679
  43. Allen BJ, Rizvi S, Li Y, Tian Z, Ranson M. In vitro and pre-clinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers. Crit Rev Oncol Hematol. 2001;39:139–146
  44. Allen BJ, Tian Z, Rizvi SMA, Li Y, Ranson M. Pre-clinical studies of targeted a therapy for breast cancer using 213Bi-labeled-plasminogen activator inhibitor type 2. Br J Cancer. 2003;88(6):944–950
  45. Aurlien E, Larsen RH, Kvalheim G, Bruland OS. Demonstration of highly specific toxicity of the α-emitting radioimmunoconjugate 211At-rituximab against non-Hodgkin's lymphoma cells. Br J Cancer. 2000;83(10):1375–1379
  46. Andersson H, Lindegren S, Back T, Jacobsson L, Leser G, Hovath G. Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labeled monoclonal antibody MOv18. Anticancer Res. 2001;20:459–462
  47. Sundberg AL, Almqvist Y, Orlova A, Blomquist E, Jensen HJ, Gedda L, et al. Combined effect of gefitinib (‘Iressa,’ ZD1839) and targeted radiotherapy with 211At-EGF. Eur J Nucl Med Mol Imaging. 2003;30:1348–1356
  48. Allen BJ, Blagojevic N. Alpha- and beta-emitting radiolanthanides in targeted cancer therapy: the potential role of 149Tb. Nucl Med Biol. 1996;17:40–47
  49. Aurlien E, Kvinnsland Y, Larsen RH, Bruland OS. Radiation doses to non-Hodgkin's lymphoma cells and normal bone marrow exposed in vitro. Comparison of an α-emitting radioimmunoconjugate and external γ-irradiation. Int J Radiat Biol. 2002;78(2):1333–1342
  50. Behr TM, Sgouros G, Stabin MG, Behe M, Angerstein C, Blumenthal RD, et al. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with α-Auger/conversion electron- or α-emitters. Clin Cancer Res. 1999;5:3031–3043
  51. Boswell CA, Brechbiel MW. Auger electrons: lethal, low energy, and coming soon to a tumor cell nucleus near you. J Nucl Med. 2005;46(12):1946–1947
  52. Behr TM, Behe M, Lohr M, Sgouros G, Angerstein C, Wehrmann E, et al. Therapeutic advantages of Auger electron- over β-emitting radiometals or radioiodine when conjugates to internalizing antibodies. Eur J Nucl Med. 2000;27(7):753–765
  53. Silberstein EB. Radionuclides and radiopharmaceuticals for 2005. J Nucl Med. 2005;46(5):13N–26N
  54. Brass JM, Krummen K, Moll-Kaufmann C. Quality assurance after process changes of the production of a therapeutic antibody. Pharm Acta Helv. 1996;71:395–403
  55. Gordon LI, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R, et al. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma. 2004;5(2):98–101
  56. Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly ×4 schedule. Blood. 2004;15:4416–4423
  57. Ellis R. Cancer docs profit from chemotherapy drugs. Accessed February 2007 at http://www.msnbc.msn.com/id/14944098/
  58. Kaden TA. Labelling monoclonal antibodies with macrocyclic radiometal complexes. A challenge for coordination chemists. Dalton Trans. 2006;3617–3623
  59. Clifford T, Boswell CA, Biddlecombe GB, Lewis JS, Brechbiel MW. Small animal PET/CT imaging using 86Y-CHX-A″-octreotide: validation of a novel CHX-A″ derivative suitable for peptide conjugation. J Med Chem. 2006;49(14):4297–4304
  60. Lee FT, Mountain AJ, Kelly MP, Hall C, Rigopoulus A, Johns TG, et al. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A″-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478. Clin Cancer Res. 2005;11:7080s–7086s
  61. Vandenbulcke K, DeVos F, Offner F, Philippe J, Apostolidis C, Molinet R, et al. In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damage. Eur J Nucl Med Mol Imaging. 2003;30(10):1357–1364
  62. Boswell CA, Sun X, Niu W, Weisman GR, Wong EH, Rheingold AL, et al. Comparative in vivo stability of 64Cu-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem. 2004;47(6):1465–1474
  63. Wadas T, Anderson CJ. Radiolabeling of TETA- and CB-TE2A-conjugated peptides with 64Cu. Nat Prot. 2007;1(6):3062–3068
  64. The Dow Chemical Co. . Accessed February 2007 at http://pharma.dow.com/chelamed/index.htm
  65. Baker M. Upping the ante on antibodies. Nat Biotechnol. 2005;23(9):1065–1072
  66. Todorovska A, Roovers RC, Dolezal O, Kortt AA, Hoogenboom HR, Hudson PJ. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods. 2001;248(1–2):47–66
  67. Wu AM, Yasaki PJ, Tsai SW, Nguyen K, Anderson AL, McCarthy DW, et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a 64Cu-labeled engineered antibody fragment. Proc Natl Acad Sci U S A. 2000;97(15):8495–8500
  68. Wong JYC, Chu DZ, Williams LE, Yamauchi DM, Ikle DN, Kwok CS, et al. Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin Cancer Res. 2004;10:5014–5021
  69. Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenograft with an 124I labeled anti-HER2 diabody. Cancer Res. 2005;65(4):1471–1478
  70. Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH, et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single chain Fv-Fc antibody fragments. Cancer Res. 2005;65:622–631
  71. Barbet J, Kraeber-Bodere F, Vuillez JP, Gautherot E, Rouvier E, Chatal JF. Pre-targeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm. 1999;14(3):153–165
  72. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pre-targeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006;24:823–834
  73. Gruaz-Guyon A, Raguin O, Barbet J. Recent advances in pre-targeted radioimmunotherapy. Curr Med Chem. 2005;12:319–338
  74. Breitz HB, Fisher DR, Goris ML, Knox S, Ratliff B, Murtha AD, et al. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pre-targeted NR-LU-10/streptavidin. Cancer Biother Radiopharm. 1999;14(5):381–395
  75. Breitz HB, Weiden PL, Beaumier PL, Axworthy DB, Seiler C, Su FM, et al. Clinical optimization of pre-targeted radioimmunotherapy with antibody–streptavidin conjugate and 90Y-DOTA-biotin. J Nucl Med. 2000;41:131–140
  76. Axworthy DB, Reno JM, Hyalarides MD, Mallett RW, Theodore LJ, Gustavson LM, et al. Cure of human carcinoma xenografts by a single dose of pre-targeted 90Y with negligible toxicity. Proc Natl Acad Sci U S A. 2000;97:1802–1807
  77. Press OW, Corcoran M, Subbiah K, Hamlin DK, Wilbur DS, Johnson T, et al. A comparative evaluation of conventional and pre-targeted radioimmunotherapy of CD20-expressing lymphomas xenografts. Blood. 2001;98(15):2535–2543
  78. Weiden PL, Breitz HB. Pre-targeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL). Crit Rev Oncol Hematol. 2001;40(1):37–51
  79. Knox S, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz HB, et al. Phase II trial of 90Y-DOTA-biotin pre-targeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res. 2000;6:406–414
  80. Sharkey RM, Cardillo TM, Rossi EA, Chang CH, Karakay H, McBride WJ, et al. Signal amplification in molecular imaging by pre-targeting a multivalent, bispecific antibody. Nat Med. 2005;11:1250–1255
  81. Roffler SR, Wang HE, Yu HM, Chang WD, Cheng CM, Lu YL, et al. A membrane antibody receptor for noninvasive imaging of gene expression. Gene Ther. 2006;13:412–420
  82. Behr TM, Sharkey RM, Juweid ME, Blumenthal RD, Dunn RM, Griffiths GL, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res. 1995;55(17):3825–3834
  83. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, et al. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res. 2001;61:4750–4755
  84. Jain M, Chauhan SC, Singh AP, Venkatraman G, Colcher D, Batra SK. Penetratin improves tumor retention of single-chain antibodies: a novel step towards optimization of radioimmunotherapy of solid tumors. Cancer Res. 2005;65(17):7840–7846
  85. Vitetta ES, Ghetie VF. Considering therapeutic antibodies. Science. 2006;313:308–309
  86. Sharpe AH, Abbas AK. T-cell costimulation — biology, therapeutic potential, and challenges. N Engl J Med. 2006;355(10):973–975
  87. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355(10):1018–1028
  88. Newsbriefs . NeutroSpec withdrawn from market. J Nucl Med. 2006;47(2):36N
  89. Albrecht H, DeNardo SJ. Recombinant antibodies: from the laboratory to the clinic. Cancer Biother Radiopharm. 2006;21(4):285–304
  90. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol. 2005;23(9):1073–1078
  91. Reichert JM. Monoclonal antibodies in the clinic. Nat Biotechnol. 2001;19:819–822
  92. Reichert JM. Therapeutic monoclonal antibodies: trends in development and approval in the US. Curr Opin Mol Ther. 2002;4(2):110–118
  93. Holliger P, Hoogenboom H. Antibodies come back from the brink. Nat Biotechnol. 1998;16:1015–1016
  94. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol. 2006;6:343–357
  95. Walsh G. Biopharmaceutical benchmarks 2006. Nat Biotechnol. 2006;24(7):769–776
  96. Wilkins DK, Mayer A. Development of antibodies for cancer therapy. Expert Opin Biol Ther. 2006;6(8):787–796
  97. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet. 2004;5:292–302
  98. von Mehren M, Adams GP, Weiner LM. Monoclonal antibody therapy for cancer. Annu Rev Med. 2003;54:343–369
  99. Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, et al. Targeted therapies for cancer 2004. Am J Clin Pathol. 2004;122:598–609
  100. White CA, Weaver RL, Grillo-Lopez AJ. Antibody-targeted immunotherapy for treatment of malignancy. Annu Rev Med. 2001;52:125–145
  101. Oriuchi H, Higuchi T, Hanaoka H, Iida Y, Endo K. Current status of cancer therapy with radiolabeled monoclonal antibody. Ann Nucl Med. 2005;19(5):355–365
  102. Ross JS, Gray K, Gray GS, Worland PJRM. Anticancer antibodies. Am J Clin Pathol. 2003;9(4):472–485
  103. Reichert JM, Pavlou A. Monoclonal antibodies market. Nat Rev Drug Disc. 2004;3:383–384
  104. Pavlou AK, Reichert JM. Recombinant protein therapeutics — success rates, market trends, and values to 2010. Nat Biotechnol. 2004;22:1513
  105. Saijo N. What are the reasons for negative phase III trials of molecular-target-based drugs?. Cancer Sci. 2004;95(10):772–776
  106. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23(9):1137–1146
  107. Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin. 2006;56:226–243
  108. Spicer J. Technology evaluation: nimotuzumab, the Center of Molecular Immunology/YM BioSciences/Oncoscience. Curr Opin Mol Ther. 2005;7(2):182–191
  109. Casaco A. Loco-regional radioimmunotherapy of high grade malignant gliomas using the humanized monoclonal antibody, h-R3, labeled with 188Re. Proc Am Soc Clin Oncol. 2004;22:[Abs 2530]
  110. Vallis KA, Reilly RM, Chen P, Oza A, Hendler A, Cameron R, et al. 99mTc-hR3 (DiaCIM), a humanized immunoconjugate directed towards the epidermal growth factor receptor. Nucl Med Commun. 2002;23(12):1155–1164
  111. Divgi C. What ails solid tumor radioimmunotherapy?. Cancer Biother Radiopharm. 2006;21(2):81–84
  112. Blumenthal RD, Kashi R, Sharkey RM, Goldenberg DM. Quantitative and qualitative effects of experimental radioimmunotherapy on tumor vascular permeability. Int J Cancer. 1995;61(4):557–566
  113. DeNardo GJ, Kennel SJ, Siegel JA, DeNardo SJ. Radiometals as payloads for radioimmunotherapy for lymphoma. Clin Lymphoma. 2004;5(S1):S5–S10
  114. Vose JM. Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma. Oncologist. 2004;9:160–172
  115. Linden O, Hindorf C, Cavallin-Stahl E, Wegener WA, Goldenberg DM, Horne H, et al. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res. 2005;11(14):5215–5222
  116. Immunomedics, Inc. . Treatment of NHL with 90Y-hLL2 IgG. Accessed February 2007 at http://www.clinicaltrials.gov/ct/show/NCT00421395
  117. Lamonica D, Czuczman M, Nabi H, Klippenstein D, Grossman Z. Radioimmunoscintigraphy (RIS) with bectumomab (99mTc-labeled IMMU-LL2, Lymphoscan) in the assessment of recurrent non-Hodgkin's lymphoma (NHL). Cancer Biother Radiopharm. 2002;17(6):689–697
  118. Blend MJ, Hyun H, Kozloff M, Levi H, Mills GQ, Gasparini M, et al. Improved staging of B-cell non-Hodgkin's lymphoma patients with 99mTc-labeled LL2 monoclonal antibody fragment. Cancer Res. 1995;55(23 Suppl S):S5764–S5770
  119. DeNardo GJ, Kukis DL, Shen S, DeNardo DJ, Meares CF, DeNardo SJ. 67Cu- versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. Clin Cancer Res. 1999;5:533–541
  120. Peregrine Pharmaceuticals, Inc. . Prospectus — September 29, 2005. Accessed February 2007; follow hyperlink to peregrine42b2.htm at http://www.sec.gov/Archives/edgar/data/704562/000101968705002707/
  121. Belch A, McEwan A, Hewitt J, Riauka T, Stabin M, Brill A, et al. Tumor targeting, dosimetry and clinical response data for LymphoRad-131 in patients with relapsed/refractory non-Hodgkin's lymphoma. Blood. 2004;104(11):214A–215A
  122. Beatty JD, Williams LE, Yamauchi D, Morton BA, Hill LR, Beatty BG, et al. Presurgical imaging with indium-labeled anti-carcinoembryonic antigen for colon cancer staging. Cancer Res. 1990;50:922s–926s
  123. Bischof-Delaloye A, Delaloye B, Buchegger F, Gilgien W, Studer A, Curchod S, et al. Clinical value of immunoscintigraphy in colorectal carcinoma patients: a prospective study. J Nucl Med. 1989;30:1646–1656
  124. Blumenthal RD, Sharkey RM, Kashi R, Goldenberg DM. Comparison of therapeutic efficacy and host toxicity of two different 131I-labeled antibodies and their fragments in the GW-39 colonic cancer xenograft model. Int J Cancer. 1989;44:292–300
  125. Scott AM, Lee FT, Jones R, Hopkins W, MacGregor D, Cebon JS, et al. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res. 2005;11:4810–4817
  126. Chong G, Lee FT, Hopkins W, Tebbut N, Cebon JS, Mountain AJ, et al. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res. 2005;11:4818–4826
  127. Buchsbaum D, Khazaeli MB, Liu TP, Bright S, Richardson K, Jones M, et al. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49. Cancer Res. 1995;55(23 Suppl S):S5881–S5887
  128. Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Schlom J, et al. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial. Clin Cancer Res. 2000;6:3095–3102
  129. Gansow OA, Wu C, Goldenberg DM. Advanced methods for radiolabeling monoclonal antibodies with therapeutic radionuclides. In:  Goldenberg DM editors. Cancer therapy with radiolabeled antibodies. Boca Raton: CRC Press; 1995;p. 63–76
  130. Immunomedics, Inc . 10-K for Immunomedics, Inc. — August 29, 2006. Accessed February 2007 at http://www.sec.gov/Archives/edgar/data/722830/000119312506181414/d10k.htm
  131. Immunomedics, Inc . Safety study of hMN14 to treat either colorectal or breast cancer. Accessed February 2007 at www.clinicaltrials.gov/ct/show/NCT00041652
  132. Immunomedics, Inc . Safety study of 90Y-hMN14 to treat pancreatic cancer. Accessed February 2007 at http://www.clinicaltrials.gov/ct/show/NCT00041639
  133. Liersch T, Meller J, Kulle B, Behr TM, Markus P, Langer C, et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol. 2005;23(27):6763–6770
  134. Immunomedics, Inc . Safety study of 90Y-hMN14 to treat colorectal cancer patients with limited residual disease after surgery. Accessed February 2007 at http://www.clinicaltrials.gov/ct/show/NCT00041691
  135. Wong JYC, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, et al. A phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res. 2003;9:5842–5852
  136. DeNardo SJ, Kramer EL, O'Donnell RT, Richman CM, Salako QA, Shen S, et al. Radioimmunotherapy for breast cancer using 111In/90Y-BrE-3: results of a phase I clinical trial. J Nucl Med. 1997;38(8):1180–1185
  137. DeNardo SJ, Richman CM, Goldstein DS, et al. Yttrium-90/Indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. Anticancer Res. 1997;17:1735–1744
  138. Richman CM, DeNardo SJ, O'Donnell RT, Yuan A, Natarajan A, Wun T, et al. Combined modality radioimmunotherapy (RIT) in metastatic prostate and breast cancer using paclitaxel and a MUC-1 monoclonal antibody, m170, linked to 90Y: a phase I trial. J Clin Oncol. 2004;22(14S):2554
  139. Schrier DM, Stemmer SM, Johnson T, Kasliwal R, Lear J, Matthes S, et al. High-dose 90Y-Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial. Cancer Res. 1995;55:5921s–5924s
  140. Ebeling FG, Stieber P, Untch M, Nagel D, Konecny GE, Schmitt UM, et al. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer. 2002;86(8):1217–1222
  141. Behr TM, Sharkey RM, Juweid ME, Dunn RM, Vagg RC, Ying Z, et al. Phase I/II clinical radioimmunotherapy with an 131I-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med. 1997;38(6):858–870
  142. Sanidas EE, Koukouraki S, Velidaki A, Manios A, Stathopoulos E, De Bree I, et al. Contribution of 99mTc-anti-carcinoembryonic antigen antibody and 99mTc-sestamibi scintimammography in the evaluation of high risk palpable breast lesions. Nucl Med Commun. 2003;24(3):291–296
  143. DeNardo SJ, Kukis DL, Miers LA, Winthrop MD, Kroger LA, Salako QA. Yttrium-90-DOTA-peptide ChL6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts. J Nucl Med. 1998;39:842–849
  144. Burke PA, DeNardo SJ, Miers L, Lamborn KR, Matzku S, DeNardo GL. Cilengitide targeting of alpha-v-beta-3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 2002;62:4263–4272
  145. DeNardo SJ, Kukis DL, Kroger LA, O'Donnell RT, Lamborn KR, Miers LA, et al. Synergy of Taxol and radioimmunotherapy with 90Y-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci U S A. 1997;94:4000–4004
  146. Burke PA, deNardo SJ, Miers LA, Kukis DL, deNardo GJ. Combined modality radioimmunotherapy: promise and peril. Cancer. 2002;94(S4):1320–1331
  147. Bander NH. Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract. 2006;3(4):216–225
  148. Raj GV, Partin AW, Polascik TJ. Clinical utility of 111In-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer. 2002;94(4):987–996
  149. Meredith RF, Bueschen AJ, Khazaeli MB, Plott WE, Grizzle WE, Wheeler RH, et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med. 1994;35(6):1017–1022
  150. Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus DM, Bander NH. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res. 2005;11(19 Pt 2):7195s–7200s
  151. O'Donnell RT, deNardo SJ, Miers LA, Lamborn KR, Kukis DL, deNardo GJ, et al. Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90Y-DOTA-peptide-ChL6. Prostate. 2002;50(1):27–37
  152. Nicodemus CF, Berek JS. Monoclonal antibody therapy of ovarian cancer. Expert Rev Anticancer Ther. 2005;5(1):87–96
  153. Epenetos AA, Hird V, Lambert H, Mason P, Coulter C. Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J Gynecol Cancer. 2000;10(Suppl 1):44–46
  154. Seiden MV, Benigno BB Group TSoMARS. A pivotal phase III trial to evaluate the efficacy and safety of adjuvant treatment with 90Y-labeled monoclonal antibody, HMFGI, in ovarian cancer. Proc Am Soc Clin Oncol. 2004;23(Suppl):16a;[Abstract 5008]
  155. Buist MR, Molthoff CFM, Kenemans P, Meijer CJLM. Distribution of Ov-Tl 3 and Mov18 in normal and malignant ovarian tissue. J Clin Pathol. 1995;48(7):631–636
  156. Buijs WC, Tibben JG, Boerman OC, Molthoff CF, Massuger LF, Koenders EB, et al. Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. Eur J Nucl Med. 1998;25(11):1552–1561
  157. Coliva A, Zacchetti A, Luison E, Tomassetti A, Bongarzone I, Seregni E, et al. 90Y labeling of monoclonal antibody MOv18 and pre-clinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunol Immunother. 2005;54:1200–1213
  158. Breitz HB, Tyler A, Bjorn MJ, Lesley T, Weiden PL. Clinical experience with 99mTc-nofetumomab merpentan (Verluma) radioimmunoscintigraphy. Clin Nucl Ned. 1997;22(9):615–620
  159. Machac J, Krynyckyi B, Kim C. Peptide and antibody imaging in lung cancer. Semin Nucl Med. 2002;32(4):276–292
  160. Forero A, Meredith RF, Khazaeli MB, Shen S, Grizzle WE, Carey D, et al. Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel administration. Cancer Biother Radiopharm. 2005;20(5):467–478
  161. Arista A, Sturiale C, Riva P, Tison V, Frattarelli M, Moscatelli G, et al. Intralesional administration of 131I-labeled monoclonal antibodies in the treatment of malignant gliomas. Acta Neurochir. 1995;135(3–4):159–162
  162. Shapiro WR, Carpenter SP, Roberts K, Shan JS. 131I-chTNT-1/B mAb: tumor necrosis therapy for malignant astrocytic glioma. Expert Opin Biol Ther. 2006;6(5):539–545
  163. Bonino LD, Demonte LB, Spagnoli GC, Vola R, Mariani M, Barone D, et al. Bispecific monoclonal antibody anti-Cd3 X anti-tenascin — an immunotherapeutic agent for human glioma. Int J Cancer. 1995;61(4):509–515
  164. Bigner DD, Brown M, Coleman RE, Friedman AH, Friedman HS, McLendon RE, et al. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan Mel-14 F(ab′)2 preliminary report. J Neurooncol. 1995;24:109–122
  165. Reardon D, Akabani G, Coleman RE, Friedman AH, Herndon J, Cokgor I, et al. Phase II trial of murine 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2002;20(5):1389–1397
  166. Akabani G, Reardon DA, Coleman RE, Wong TZ, Metzler SD, Bowsher JE, et al. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med. 2005;46(6):1042–1051
  167. Paganelli G, Bartolomei M, Ferrari M, Cremonesi M, Broggi G, Maira G, et al. Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: Phase I study and preliminary therapeutic results. Cancer Biother Radiopharm. 2001;16(3):227–235
  168. Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, de Cicco C, et al. Pre-targeted adjuvant radioimmunotherapy with 90Y-biotin in malignant glioma patients: a pilot study. Br J Cancer. 2002;86:207–212
  169. Divgi CR, Bander NH, Scott AM, O'Donoghue JA, Sgouros G, Welt S, et al. Phase I/II radioimmunotherapy trial with 131I-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res. 1998;4:2729–2739
  170. Divgi CR, O'Donoghue JA, Welt S, O'Neel J, Finn RD, Motzer RJ, et al. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med. 2004;45(8):1412–1421
  171. Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother. 2003;52:281–296
  172. Projection based on Sg2 Imaging Forcast, U.M.-S., Skokie, IL (www.sg2.com).
  173. Kang DE, White RL, Zuger JH, Sasser HC, Teigland CM. Clinical use of fluorodeoxyglucose 18F positron emission tomography for detection of renal cell carcinoma. J Urol. 2004;171:1806–1809
  174. Libutti SK, Alexander HR, Choyke PL, Bartlett DL, Bacharach SL, Whatley M, et al. A prospective study of 2-[18F] fluoro-2-deoxy-d-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-Scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. Ann Surg Oncol. 2001;8:779–786
  175. Wittes RE. Cancer weapons, out of reach. The Washington Post June 28, 2004.
  176. Choyke PL. Invited commentary. Radiographics. 2006;26:1806–1810

☆ Portions of this article were highlighted during a presentation at the Workshop on Molecular Imaging: After Bench to Bedside: Impact on Clinical Outcome, February 23–25, 2007.

PII: S0969-8051(07)00092-3

doi: 10.1016/j.nucmedbio.2007.04.001

Nuclear Medicine and Biology
Volume 34, Issue 7 , Pages 757-778 , October 2007

Article Tools